Information about Dolutegravir
Dolutegravir is a human immunodeficiency virus (HIV) integrase inhibitor, the third in this class of agents that target the viral integrase. Dolutegravir is used only in combination with other antiretroviral agents in the treatment of HIV infection, and it has had limited use.
Liver safety of Dolutegravir
Mechanism of action of Dolutegravir
Dolutegravir (doe" loo teg' ra vir) is relatively new antiretroviral drug that targets the HIV integrase, one of the three viral enzymes involved in replication. Dolutegravir blocks the binding site of the HIV integrase and prevents the strand transfer activity and integration of the provirus into the host genome. Dolutegravir has both in vitro and in vivo activity against HIV, and several randomized controlled trials have shown that it can cause significant declines in HIV RNA levels and rises in peripheral [[CD4 T cell counts].
FDA approval information for Dolutegravir
Dolutegravir was approved for use in HIV infection in the United States in 2013 and is currently used in an increasing proportion of antiretroviral regimens.
Dosage and administration for Dolutegravir
Dolutegravir is available as 50 mg tablets under the brand name Tivicay. The recommended dose regimen is 50 mg twice daily in combination with other classes of antiretroviral agents. A single tablet, fixed dose regimen of dolutegravir [50 mg], abacavir [600 mg] and lamivudine [300 mg] is also available under the name Triumeq, the recommended dose being one tablet daily.
Side effects of Dolutegravir
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza